At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 98 enrolled
Drug / intervention
Biological: TCR alfa beta T cell depletionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II/III Study of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated and Haploidentical Donors After TCR Alfa Beta Negative Selection in Pediatric Patients With Primary Immunodeficiency Diseases
Federal Research Institute of Pediatric Hematology, Oncology and Immunology·interventional·Posted Dec 30, 2014·Updated Feb 26, 2021
In Brief
A Phase 3 clinical trial evaluating Biological: TCR alfa beta T cell depletion for Primary Immune Deficiency Disorder and Hematopoietic Stem Cell Transplantation. Completed, enrolled 98 participants across 1 site.
Detailed Summary
Treatment Study to assess of safety and efficiency of T cells receptor (TCR) alfa beta depleted graft for hematopoietic stem cell transplantation (HSCT) from haploidentical and unrelated donors in patients with primary immunodeficiency diseases
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedDec 2014
Primary CompletionDec 2017
Study CompletionJun 2018
TodayJul 2026
First PostedDec 30, 2014
Enrollment StartJul 1, 2012
Primary CompletionDec 1, 2017
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.5 years ago
Interventions
Biological: TCR alfa beta T cell depletionother